Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:5041 |
| Name | esophageal cancer |
| Definition | A gastrointestinal system cancer that is located_in the esophagus. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:10291 DOID:1104 DOID:1102 DOID:10292 DOID:10448 |
| Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer esophageal cancer |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| HRAS Q61L | IHMT-RAF-128 | esophageal cancer | sensitive | detail... |
| SMARCA4 mutant | PRT3789 | esophageal cancer | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01037790 | Phase II | Palbociclib | PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER | Completed | USA | 0 |
| NCT01128387 | Phase Ib/II | Fluorouracil Panitumumab Cisplatin | Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer | Terminated | USA | 0 |
| NCT01325441 | Phase Ib/II | Napabucasin + Paclitaxel | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | Completed | USA | CAN | 0 |
| NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
| NCT01522768 | Phase II | Afatinib + Paclitaxel | Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer | Completed | USA | 0 |
| NCT01848756 | Phase Ib/II | SNX-5422 | Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers | Terminated | USA | 0 |
| NCT01928290 | Phase II | Trastuzumab Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer | Completed | USA | 0 |
| NCT02375958 | Phase I | PCA062 | PCA062 in pCAD-positive Tumors. | Completed | USA | ITA | FRA | ESP | 2 |
| NCT02569242 | Phase III | Docetaxel + Paclitaxel Nivolumab | Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer | Completed | USA | ITA | GBR | DNK | DEU | 3 |
| NCT02715531 | Phase I | Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | Completed | USA | NZL | AUS | 4 |
| NCT02749513 | Phase I | Itraconazole | Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients | Unknown status | USA | 0 |
| NCT02960594 | Phase I | INO-1400 + Rocakinogene sifuplasmid INO-1400 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | Completed | USA | 0 |
| NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
| NCT02970539 | Phase I | Oraxol + Ramucirumab | Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers | Unknown status | USA | 1 |
| NCT03044613 | Phase I | Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel | Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer | Active, not recruiting | USA | 0 |
| NCT03126110 | Phase Ib/II | INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | Completed | USA | ESP | BEL | AUS | 0 |
| NCT03132922 | Phase I | afamitresgene autoleucel | MAGE-A4c1032T for Multi-Tumor | Active, not recruiting | USA | CAN | 0 |
| NCT03144661 | Phase I | INCB062079 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | Terminated | USA | BEL | 0 |
| NCT03199586 | Phase I | NP-G2-044 | Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) | Completed | USA | 0 |
| NCT03233724 | Phase Ib/II | Pembrolizumab | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | Terminated | USA | 0 |
| NCT03281369 | Phase Ib/II | Atezolizumab + Cobimetinib Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Linagliptin Atezolizumab + PEGPH20 Atezolizumab + BKT140 Paclitaxel + Ramucirumab Cisplatin + Fluorouracil Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Tiragolumab | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Active, not recruiting | USA | ISR | GBR | ESP | AUS | 2 |
| NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT03330561 | Phase I | Cinrebafusp alfa | PRS-343 in HER2-Positive Solid Tumors | Completed | USA | 0 |
| NCT03477162 | Phase 0 | Metformin | Metformin Pharmacology in Human Cancers: A Proof of Principle Study | Terminated | USA | 0 |
| NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
| NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
| NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Completed | USA | CAN | 1 |
| NCT03621982 | Phase I | Camidanlumab tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Terminated | USA | GBR | BEL | 0 |
| NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
| NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
| NCT03720678 | Phase I | Etrumadenant + Fluorouracil + Leucovorin + Oxaliplatin | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies | Completed | USA | AUS | 0 |
| NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Terminated | USA | POL | ITA | HUN | GBR | 1 |
| NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Terminated | USA | FRA | BEL | AUS | 1 |
| NCT03973333 | Phase Ib/II | Atezolizumab + IMC-C103C IMC-C103C | Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab | Withdrawn | USA | GBR | ESP | 0 |
| NCT04018872 | Phase II | Itraconazole | Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer | Recruiting | USA | 0 |
| NCT04044859 | Phase I | afamitresgene autoleucel afamitresgene autoleucel + Pembrolizumab afamitresgene autoleucel + Nivolumab | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | Active, not recruiting | USA | ESP | CAN | 0 |
| NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Completed | USA | 0 |
| NCT04157985 | Phase III | Nivolumab Ipilimumab Cemiplimab Pembrolizumab Atezolizumab | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT04225117 | Phase II | Enfortumab vedotin-ejfv | A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Active, not recruiting | USA | CAN | 1 |
| NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
| NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Terminated | USA | GBR | ESP | DEU | 1 |
| NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
| NCT04287868 | Phase Ib/II | Bintrafusp alfa + NHS-IL12 + PDS0101 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | Active, not recruiting | USA | 0 |
| NCT04336241 | Phase I | Nivolumab + RP2 RP2 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Recruiting | GBR | ESP | 0 |
| NCT04389632 | Phase I | SGN-B6A | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CHE | 2 |
| NCT04419532 | Phase I | DS-1055a | A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | CAN | 1 |
| NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
| NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Terminated | USA | ISR | ESP | DNK | 0 |
| NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
| NCT04491942 | Phase I | Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT04561362 | Phase Ib/II | BT8009 BT8009 + Pembrolizumab | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | 0 |
| NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
| NCT04665921 | Phase I | SGN-STNV | A Study of SGN-STNV in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
| NCT04708470 | Phase Ib/II | Bintrafusp alfa + Entinostat + NHS-IL12 Entinostat + NHS-IL12 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | Active, not recruiting | USA | 0 |
| NCT04772989 | Phase I | AB308 + Zimberelimab | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12) | Completed | USA | POL | ESP | 0 |
| NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Recruiting | USA | 0 |
| NCT04837677 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT04914286 | Phase Ib/II | GFH018 + Toripalimab-tpzi | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Completed | AUS | 1 |
| NCT05057013 | Phase Ib/II | HMBD-001 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | Active, not recruiting | GBR | 0 |
| NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
| NCT05076591 | Phase I | IMM2902 | IMM2902, a HER2/SIRPalpha Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors | Suspended | USA | 0 |
| NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | IRL | ESP | CAN | AUS | 2 |
| NCT05117476 | Phase I | CLN-619 Carboplatin + CLN-619 + Paclitaxel + Pemetrexed Disodium CLN-619 + Pembrolizumab CLN-619 + Datopotamab deruxtecan | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MICA) | Active, not recruiting | USA | POL | ESP | AUS | 0 |
| NCT05306444 | Phase I | HBM7008 | CLN-418 Study on Subjects With Advanced Solid Tumors | Completed | USA | AUS | 0 |
| NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
| NCT05438420 | Phase Ib/II | Adrixetinib + Pembrolizumab | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Terminated | USA | AUS | 0 |
| NCT05547321 | Phase I | OMTX705 + Pembrolizumab OMTX705 + Tislelizumab OMTX705 | Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. | Recruiting | USA | ESP | 0 |
| NCT05563766 | Phase II | Itraconazole | A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | Recruiting | USA | 0 |
| NCT05565417 | Phase Ib/II | Fruquintinib + IMT-009 IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas | Active, not recruiting | USA | 0 |
| NCT05572684 | Phase Ib/II | NC410 + Pembrolizumab | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
| NCT05677490 | Phase III | Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Recruiting | USA | 1 |
| NCT05830097 | Phase Ib/II | CBP-1019 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT05891171 | Phase I | AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) | Active, not recruiting | USA | AUS | 1 |
| NCT05898828 | Phase Ib/II | Entinostat + H1299 cell lysate vaccine + Montanide ISA 51 + Nivolumab | Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | Withdrawn | USA | 0 |
| NCT05947474 | Phase I | ORB-011 | ORB-011 In Patients With Advanced Solid Tumors (ORB) | Active, not recruiting | USA | 0 |
| NCT05964361 | Phase Ib/II | IL15-TransDC | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients | Active, not recruiting | BEL | 0 |
| NCT05980416 | Phase I | EO-3021 | Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 | Terminated | USA | 2 |
| NCT05983432 | Phase I | BL-B01D1 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Recruiting | USA | 0 |
| NCT05985083 | Phase I | IMM47 | A Study Of IMM47 In Subjects With Advanced Solid Tumors | Unknown status | AUS | 0 |
| NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
| NCT06238479 | Phase I | LY4101174 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | BEL | AUS | 2 |
| NCT06242691 | Phase II | MK-1200 | Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors | Completed | USA | ISR | AUS | 3 |
| NCT06293898 | Phase I | BL-M07D1 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Recruiting | USA | 0 |
| NCT06465069 | Phase I | LY4052031 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) | Recruiting | USA | GBR | FRA | ESP | AUS | 2 |
| NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
| NCT06597721 | Phase I | AMT-754 | AMT-754 in Patients With Selected Advanced Solid Tumours | Recruiting | USA | AUS | 0 |
| NCT06682806 | Phase II | Pembrolizumab + PRT3789 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | Active, not recruiting | USA | ESP | 0 |
| NCT06760481 | Phase I | Atezolizumab + Tiragolumab Atezolizumab | Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER) | Active, not recruiting | USA | 0 |
| NCT06799533 | Phase I | PF-08046031 | A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors | Active, not recruiting | USA | SWE | GBR | FRA | ESP | 0 |
| NCT06943521 | Phase Ib/II | MT-4561 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT07090499 | Phase I | PF-08046876 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT07163325 | Phase I | EP102 | EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors | Recruiting | NLD | ESP | CZE | BEL | 0 |
| NCT07218003 | Phase I | RNDO-564 Pembrolizumab + RNDO-564 | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | Recruiting | USA | 0 |
| NCT07223424 | Phase II | Pembrolizumab Nivolumab | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune) | Recruiting | USA | 0 |
| NCT07227168 | Phase I | Pembrolizumab + STRO-004 STRO-004 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Recruiting | USA | 0 |